ArticleApplied immunohistochemistry & molecular morphology : AIMM2026
TRPS1 Expression Across the Spectrum of Paget Disease and Morphologic Mimics.
Article in Applied immunohistochemistry & molecular morphology : AIMM, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paget disease (PD) is histologically characterized by malignant glandular epithelial cells singly or in clusters within the epidermis. PD most commonly involves the nipple, though it may also occur at extramammary sites. Immunohistochemistry is helpful in highlighting PD and its extent. Differentiating PD from histologic mimics with overlapping immunophenotypes can be challenging. TRPS1, a GATA family transcription factor, has emerged as a breast origin marker with greater sensitivity than GATA3. In this study, we comprehensively examined the immunohistochemical expression of TRPS1 in mammary PD (n=29) with different biomarker profiles, including ER - /HER2 + (n=12), ER + /HER2 + (n=7), ER + /HER2 - (n=6), and ER - /HER2 - (n=4) cases, as well as benign and malignant histologic mimics and extramammary PD (EMPD). TRPS1 demonstrated strong to moderate nuclear staining of PD tumor cells across all ER/HER2 subgroups. Toker cells/Toker cell hyperplasia (n=11) also exhibited strong TRPS1 immunoreactivity, while melanoma in situ (n=10) and cutaneous sebaceous carcinoma (n=9) were essentially negative. Squamous cell carcinoma in situ (n=13) showed predominantly weak staining for TRPS1. Two cases of presumed intraepidermal metastases in patients with breast cancer demonstrated strong TRPS1 expression. Notably, TRPS1 highlighted PD tumor cells from background keratinocytes more distinctly compared with GATA3. Among EMPD cases, perivulvar (n=10) and periscrotal (n=5) cases were consistently positive, whereas perianal lesions (n=10) showed no/weak expression. In summary, TRPS1 demonstrates universal expression in mammary PD of all ER/HER2 subgroups and in Toker cells, and corroborates recent reports regarding the utility of TRPS1 in site-of-origin studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.